Emisphere Technologies Inc., of Roseland, N.J., reached agreement with MHR Fund Management LLC and certain of its affiliated funds to finance the upcoming launch of the company's first commercial prescription product, oral Eligen B12 for B12-deficient people in the U.S. through a new loan facility, and to amend the terms of the company's existing obligations under various promissory notes previously issued to MHR to extend their maturity dates.